# Combined top 10 from each PICO category for RECOTESTMOLPOUM25_CBNPC_tests_moléculaires_cleaned.json

## Population

1. (Patients, score 8) on–Small-Cell Lung Cancer: American Society of Clinical
Oncology Clinical Practice Guideline Update Nasser Hanna et al. Journal of Clinical
Oncology 2017 35:30, 3484-3515
• Les recommandations du College of American Pathologists (CAP) concernant les tests
moléculaires devant être effectués pour les patients atteints de CBNPC : Kalemkerian GP et al.
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With
Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the
College of American Pathologists/International Association for the St

2. (Patients, score 8) Nasser Hanna et al. Journal of Clinical
Oncology 2017 35:30, 3484-3515
• Les recommandations du College of American Pathologists (CAP) concernant les tests
moléculaires devant être effectués pour les patients atteints de CBNPC : Kalemkerian GP et al.
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With
Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the
College of American Pathologists/International Association for the Study of Lung
Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. 2018 ;
•

3. (Patients, score 7) s for diagnosis, treatment and follow-up, published in 2017 – Ann Oncol (2017)
28: iv1-iv21, updated in September 2021,
o NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer Version 5.2023
—August 11th, 2023,
o Recommendations for the use of next-generation sequencing (NGS) for patients with
metastatic cancers: a report from the ESMO Precision Medicine Working Group – Ann
Oncol 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020
Aug 24,
o NICE guideline [NG122] Lung cancer: diagnosis and management Published date: March
o Systemic Therapy for Stage IV Non–Small

4. (Patients, score 7) car le stade investigué était IIIB-IV
5 articles sélectionnés et 1 article ajouté par les experts : pas de résultat de nature à faire évoluer les
recommandations internationales
1. PMID: 37236398
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib
in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3
ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong
V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS,
Ma

5. (Patients, score 7) , Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS,
Majem M. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023
May 24. PMID: 37236398 Free article. Clinical Trial.
2. PMID: 36863124
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung
adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, Wang J, Wang R, Ji C, Li S, Wang Y, Yan S, Lu F, Pei Y, Liu Y, Yang
Y. Lung Cancer. 2023 Apr;178:151-156. doi: 10.1016/j.lungcan.2023.0

6. (Patients, score 7) b 24;8(1):76. doi: 10.1038/s41392-022-01286-3. PMID: 36823150 Free
PMC article. Clinical Trial.
4. PMID: 36369159
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm
study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with
stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt
RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F,
Nagasaka M, Pass HI, Schulze K, Johnson A

7. (Patients, score 7) Kwiatkowski DJ, Wistuba
II, Chaft JE, Carbone DP, Lee JM. J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. doi:
10.1016/j.jtcvs.2022.10.007. EPub 2022 Oct 8. PMID: 36369159 Free PMC article. Clinical Trial.
5. PMID: 36355317
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-
mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study
(ICAPE).
Qian K, Chen QR, He M, Wang ZT, Liu Y, Liang HG, Su ZY, Cui YS, Liu LJ, Zhang Y. Invest New Drugs.
Recherche du statut PD-L1 pour immunothérapie
Recherche complémentai

8. (Patients, score 7) eli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA. Ann Oncol. 2023
Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17. PMID: 37467930 Free
article. Clinical Trial.
2. PMID: 37146754
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With
Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S,
Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-
Ares LG, Ramalingam SS, Bor

9. (Patients, score 6) itement du CBNPC avancé avec réarrangement du gène ALK-
positif chez les patients adultes ;
- dans le traitement du CBNPC avancé avec réarrangement du gène ALK-positif chez
les patients adultes préalablement traités par crizotinib.
Est indiqué en monothérapie :
- en première ligne de traitement des patients adultes ayant un CBNPC avancé avec un
réarrangement du gène ALK-positif ;
- dans le traitement du CBNPC avancé ALK-positif chez les patients adultes
préalablement traités par crizotinib.
Est indiqué en monothérapie :
- pour le traitement des patients adultes atteints d’un CBNPC avancé présentant un

10. (Patients, score 5) adultes ayant un CBNPC ALK-positif et
avancé ;
- dans le traitement des patients adultes ayant reçu au moins un traitement antérieur
pour un CBNPC ALK-positif et avancé.
Est indiqué en monothérapie :
- en première ligne de traitement du CBNPC avancé avec réarrangement du gène ALK-
positif chez les patients adultes ;
- dans le traitement du CBNPC avancé avec réarrangement du gène ALK-positif chez
les patients adultes préalablement traités par crizotinib.
Est indiqué en monothérapie :
- en première ligne de traitement des patients adultes ayant un CBNPC avancé avec un
réarrangement du gène ALK-positif

## Intervention

1. (Therapy, score 8) BE, Kris MG, Kwiatkowski DJ, Wistuba
II, Chaft JE, Carbone DP, Lee JM. J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. doi:
10.1016/j.jtcvs.2022.10.007. EPub 2022 Oct 8. PMID: 36369159 Free PMC article. Clinical Trial.
5. PMID: 36355317
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-
mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study
(ICAPE).
Qian K, Chen QR, He M, Wang ZT, Liu Y, Liang HG, Su ZY, Cui YS, Liu LJ, Zhang Y. Invest New Drugs.
Recherche du statut PD-L1 pour immunothérapie
Recherche

2. (Treatment, score 7) ao W, Xu S, Ma H, Wang J, Wang R, Ji C, Li S, Wang Y, Yan S, Lu F, Pei Y, Liu Y, Yang
Y. Lung Cancer. 2023 Apr;178:151-156. doi: 10.1016/j.lungcan.2023.02.011. Epub 2023 Feb 17. PMID:
36863124 Free article. Clinical Trial.
3. PMID: 36823150
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant
non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised
phase II trial.
Zhong WZ, Yan HH, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y,
Xu L, Wang CL, Chen MW, Kang XZ, Yan WP, Liao RQ, Yang JJ, Zhan

3. (Treatment, score 3) 1) :
o Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up – Ann Oncol (2023) volume 34, April
2023, pp358-376,
o Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up – Ann Oncol (2023) volume 34, April
2023, pp339-357,
o Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up, published in 2017 – Ann Oncol (2017)
28: iv1-iv21, updated in September 2021,
o NCCN Clinical

4. (Treatment, score 3) .
Frost N, Bleckmann A, Griesinger F, Grohé C, Janning M, Kollmeier J, Reinmuth N, Sebastian M,
Thomas M, Reck M. Clin Lung Cancer. 2023 Sep;24(6):568-572. doi: 10.1016/j.cllc.2023.04.009. EPub
2023 Apr 23. PMID: 37169628 Clinical Trial.
4. PMID: 37676681
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung
Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S,
Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K;
West Jap

5. (Treatment, score 2) .
Ils se sont appuyés sur :
• les recommandations de pratique clinique publiées le plus récemment par les grands
émetteurs internationaux : ESMO, NCCN, NICE et ASCO (analyse en Annexe 1) :
o Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up – Ann Oncol (2023) volume 34, April
2023, pp358-376,
o Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up – Ann Oncol (2023) volume 34, April
2023, pp339-357,
o Early and locally advanced non-small-cell lung

6. (Treatment, score 2) ,
o Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up – Ann Oncol (2023) volume 34, April
2023, pp339-357,
o Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up, published in 2017 – Ann Oncol (2017)
28: iv1-iv21, updated in September 2021,
o NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer Version 5.2023
—August 11th, 2023,
o Recommendations for the use of next-generation sequencing (NGS) for patients with
metastatic c

7. (Treatment, score 2) Clinical
Oncology 2017 35:30, 3484-3515
• Les recommandations du College of American Pathologists (CAP) concernant les tests
moléculaires devant être effectués pour les patients atteints de CBNPC : Kalemkerian GP et al.
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With
Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the
College of American Pathologists/International Association for the Study of Lung
Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. 2018 ;
• les recommandations nationales

8. (Treatment, score 2) Tanaka H, Hotta K, Sugawara S,
Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H. Int J Clin Oncol. 2023
Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7. PMID: 37548831 Free
PMC article. Clinical Trial.
6. PMID: 37557022
Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial
evaluating geriatric and quality-of-life outcomes.
Blanco R, Dómine M, González JL, Loutfi S, Alfaro J, Saldaña J, Rubio J, Campos B, Hidalgo J, Barba A,
Márquez D, Martin M, Olaverri A, Nadal E. Lung Cancer. 2023 Sep;183:107318. doi:
10

9. (Therapy, score 2) sequencing (NGS) for patients with
metastatic cancers: a report from the ESMO Precision Medicine Working Group – Ann
Oncol 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014. Epub 2020
Aug 24,
o NICE guideline [NG122] Lung cancer: diagnosis and management Published date: March
o Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical
Oncology Clinical Practice Guideline Update Nasser Hanna et al. Journal of Clinical
Oncology 2017 35:30, 3484-3515
• Les recommandations du College of American Pathologists (CAP) concernant les tests
moléculaires devant être effe

10. (Therapy, score 2) iuranpong
V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS,
Majem M. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023
May 24. PMID: 37236398 Free article. Clinical Trial.
2. PMID: 36863124
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung
adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, Wang J, Wang R, Ji C, Li S, Wang Y, Yan S, Lu F, Pei Y, Liu Y, Yang
Y. Lung Cancer. 2023 Apr;178:151-156. doi: 10.1016/j.lu

## Comparator

## Outcome

1. (Efficacy, score 3) , Liu SY, Zhou Q, Wu YL. Signal
Transduct Target Ther. 2023 Feb 24;8(1):76. doi: 10.1038/s41392-022-01286-3. PMID: 36823150 Free
PMC article. Clinical Trial.
4. PMID: 36369159
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm
study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with
stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt
RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doeb

2. (Safety, score 3) u Q, Wu YL. Signal
Transduct Target Ther. 2023 Feb 24;8(1):76. doi: 10.1038/s41392-022-01286-3. PMID: 36823150 Free
PMC article. Clinical Trial.
4. PMID: 36369159
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm
study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with
stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt
RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Bac

3. (Safety, score 2) , English, French, from 2023
8 articles obtenus : trois articles n’ont pas été sélectionnés, car le stade investigué était IIIB-IV
5 articles sélectionnés et 1 article ajouté par les experts : pas de résultat de nature à faire évoluer les
recommandations internationales
1. PMID: 37236398
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib
in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3
ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong
V, Me

